If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
In 1896, Viennese dermatologist Leopold Freund (1868-1943) used X-rays to treat patients for the first time. He successfully irradiated the hairy nevus of a young girl. In 1897, Hermann Gocht (1869–1931) published the treatment of trigeminal neuralgia with X-rays, and Alexei Petrovich Sokolov (1854-1928) wrote about radiotherapy for arthritis in the oldest radiology journal, Advances in the field of X-rays (RöFo). In 1922, X-rays were recommended as safe for many diseases and for diagnostic purposes. Radiation protection was limited to recommending doses that would not cause erythema (reddening of the skin). For example, X-rays were promoted as an alternative to tonsillectomy. It was also boasted that in 80% of cases of diphtheria carriers, Corynebacterium diphtheriae was no longer detectable within two to four days. In the 1930s, Günther von Pannewitz (1900–1966), a radiologist from Freiburg, Germany, perfected what he called X-ray stimulation radiation for degenerative diseases. Low-dose radiation reduces the inflammatory response of tissues. Until about 1960, children with diseases such as ankylosing spondylitis or favus (head fungus) were irradiated, which was effective but led to increased cancer rates among patients decades later. In 1926, the American pathologist James Ewing (1866-1943) was the first to observe bone changes as a result of radiotherapy, which he described as radiation osteitis (now Osteoradionecrosis). In 1983, Robert E. Marx stated that osteoradionecrosis is radiation-induced aseptic bone necrosis.
== History == In 1997, Hong Kong molecular biologist Dennis Lo and his team first employed the Y-PCR assay to identify fetal Y chromosome sequences (because Y-specific sequences are genetic sequences of the fetus not in the maternal genome) in maternal plasma samples. For this groundbreaking work, Lo was honored with the 2022 Lasker DeBakey Clinical Medical Research Award.
== External links == Clinical trial number NCT03500549 for "Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)" at ClinicalTrials.gov Clinical trial number NCT03525613 for "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration " at ClinicalTrials.gov Clinical trial number NCT03525600 for "Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration " at ClinicalTrials.gov
Throughout most of the war, the National Revolutionary Army issued rations consisting solely of rice to its soldiers, supplying an average of 2.5 cups of rice per day. Soldiers were expected to forage for additional foods such as wild onions, garlic, mushrooms, and leeks to eat with their rice and to purchase extra food in local markets with their military pay. Their ability to purchase food varied with price fluctuations. Rationing proved a point of contention between Chinese commanders and their American advisors, who insisted that Chinese soldiers were underfed and in particular required more meat. In February 1945 a new ration was officially adopted in a Sino-American conference which incorporated rice, vegetables, beans, peanuts, salt, and meat, with alternatives such as eggs and fish for when meat was unavailable, but implementation proved difficult in practice. The German Wehrmacht received basic rations of hard bread and canned meat (usually pork, roast beef, turkey, or chicken, though cans labeled Fleischkonserve—literally translated as "can of meat"—went unidentified), with each soldier typically carrying a daily supply consisting of a 11-ounce (300 g) tin of meat and a 4.4-to-5.3-ounce (125 to 150 g) piece of hard bread. Soldiers were also issued canned tomato soup, condensed milk, and Erbswurst (a compact peasemeal sausage that can be dissolved to make pea soup). Elite units received more unique high-energy food.
Cross-flowing is a passive formation method that involves the continuous and aqueous phases running at an angle to each other. Most commonly, the channels are perpendicular in a T-shaped junction with the dispersed phase intersecting the continuous phase; other configurations such as a Y-junction are also possible. The dispersed phase extends into the continuous and is stretched until shear forces break off a droplet. In a T-junction, droplet size and formation rate are determined by the flow rate ratio and capillary number. The capillary number relates the viscosity of the continuous phase, the superficial velocity of the continuous phase, and the interfacial tension. Typically, the dispersed phase flow rate is slower than the continuous flow rate. T-junction formation can be further applied by adding additional channels, creating two T-junctions at one location. By adding channels, different dispersed phases can be added at the same point to create alternating droplets of different compositions. Droplet size, usually above 10 μm, is limited by the channel dimensions and often produces droplets with a CV of less than 2% with a rate of up to 7 kHz.
Sources: en.wikipedia.org
== History == The glyoxylate cycle was discovered in 1957 at the University of Oxford by Sir Hans Kornberg and his mentor Hans Krebs, resulting in a Nature paper Synthesis of Cell Constituents from C2-Units by a Modified Tricarboxylic Acid Cycle. Kornberg and Krebs utilized isotopic labeling with C-14 acetate to demonstrate that in the glyoxylate pathway, the acetate is incorporated into the succinate intermediate while bypassing the decarboxylation steps of the TCA cycle. Their results from isotopic experiments laid the foundation for the alternative glyoxylate cycle and explained how plants as well as microorganisms convert two-carbon molecules into carbohydrates. Following this discovery, in 1967 Breidenbach and Beevers discovered that there is a specialized organelle in castor bean (Ricinus communis), glyoxysomes, which are specialized peroxisomes where the glyoxylate cycle enzymes are found and where the cycle takes place in plants.
== Uses == Historically, shell cordovan was used for razor strops to hone razors in barber shops. It is used mostly in the manufacture of shoes, including high-end shoemaking, and is also used for wallets and watch straps due to its visual appeal and durability. In archery, it is used to protect the fingers and is considered smooth and durable, ideal for a finger tab. Outside leather crafting, "cordwain" denotes a leather-grain embossed cover paper used for folders, covers, and similar applications in commercial printing.
Surrounds heart and bases of pulmonary artery and aorta. Deep to sternum and anterior chest wall. The right phrenic nerve passes to the right of the pericardium. The left phrenic nerve passes over the pericardium of the left ventricle. Pericardial arteries supply blood to the dorsal portion of the pericardium.
The Birman, also called the "Sacred Cat of Burma", is a domestic cat breed. The Birman is a long-haired, colour-pointed cat distinguished by a silky coat, deep blue eyes, and contrasting white "gloves" on each paw. The breed name is derived from Birmanie, the French form of Burma. The breed was first recognised in 1925 in France.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.